FibroScan®
Article | 03.05.2021
Blog and news
topic :
category :
status :
Article | 22.04.2021
FibroScan® 630 Expert: Complete, Non-invasive Solution Offers Effective Management and Risk Stratification for Patients with Cirrhosis and Portal Hypertension
Webinar | 10.04.2021
Strategies For Identification of NAFLD NASH in T2DM Using Non Invasive Diagnostic Tools
Webinar | 10.04.2021
Spleen Stiffness – The Noninvasive Alternative For Assessment of Portal Hypertension & Esophageal Varices Risk
Article | 09.04.2021
Diabetes Wake-Up Call: Liver Screening Tools Help Battle Obesity-Related Diseases
Article | 09.04.2021
Fatty Liver Disease Impacts Minority Populations: April 2021 is National Minority Health Month
Article | 09.04.2021
COVID-19 Impact: Higher Risks of Severity Among Obese and Chronic Liver Disease Patients
Article | 09.04.2021
FibroScan® Recommended for Hepatitis C Patients
Article | 09.04.2021
Understanding the Link Between Cardiovascular Disease and Liver Disease
Article | 09.04.2021
Echosens Observes National Drug and Alcohol Facts Week 2021
Article | 09.04.2021
Better Health for the Long Haul: Echosens and Healthy Trucking of America Collaborate
Article | 09.04.2021
Noninvasive Tests Cost-Effectively Identify Patients at Risk for Liver Disease
Article | 09.04.2021
Echosens Featured in OncologyTube
Article | 09.04.2021
Comprehensive Economical Analysis Shows Screening Diabetic Patients for NAFLD is Cost Effective in the United States
Press Release | 09.04.2021